304 related articles for article (PubMed ID: 30612138)
1. Inappropriate glucagon and GLP-1 secretion in individuals with long-standing type 1 diabetes: effects of residual C-peptide.
Thivolet C; Marchand L; Chikh K
Diabetologia; 2019 Apr; 62(4):593-597. PubMed ID: 30612138
[TBL] [Abstract][Full Text] [Related]
2. Mixed Meal and Intravenous L-Arginine Tests Both Stimulate Incretin Release Across Glucose Tolerance in Man: Lack of Correlation with β Cell Function.
Ruetten H; Gebauer M; Raymond RH; Calle RA; Cobelli C; Ghosh A; Robertson RP; Shankar SS; Staten MA; Stefanovski D; Vella A; Wright K; Fryburg DA;
Metab Syndr Relat Disord; 2018 Oct; 16(8):406-415. PubMed ID: 30117761
[TBL] [Abstract][Full Text] [Related]
3. Patients With Long-QT Syndrome Caused by Impaired
Hyltén-Cavallius L; Iepsen EW; Wewer Albrechtsen NJ; Svendstrup M; Lubberding AF; Hartmann B; Jespersen T; Linneberg A; Christiansen M; Vestergaard H; Pedersen O; Holst JJ; Kanters JK; Hansen T; Torekov SS
Circulation; 2017 May; 135(18):1705-1719. PubMed ID: 28235848
[TBL] [Abstract][Full Text] [Related]
4. Effect of GLP-1 and GIP on C-peptide secretion after glucagon or mixed meal tests: Significance in assessing B-cell function in diabetes.
Guglielmi C; Del Toro R; Lauria A; Maurizi AR; Fallucca S; Cappelli A; Angeletti S; Lachin JM; Pozzilli P
Diabetes Metab Res Rev; 2017 Sep; 33(6):. PubMed ID: 28371189
[TBL] [Abstract][Full Text] [Related]
5. Effect of glucagon-like peptide-1 on alpha- and beta-cell function in C-peptide-negative type 1 diabetic patients.
Kielgast U; Asmar M; Madsbad S; Holst JJ
J Clin Endocrinol Metab; 2010 May; 95(5):2492-6. PubMed ID: 20207828
[TBL] [Abstract][Full Text] [Related]
6. Mixed meal ingestion diminishes glucose excursion in comparison with glucose ingestion via several adaptive mechanisms in people with and without type 2 diabetes.
Alsalim W; Tura A; Pacini G; Omar B; Bizzotto R; Mari A; Ahrén B
Diabetes Obes Metab; 2016 Jan; 18(1):24-33. PubMed ID: 26354383
[TBL] [Abstract][Full Text] [Related]
7. Acute metabolic effects of exenatide in patients with type 1 diabetes with and without residual insulin to oral and intravenous glucose challenges.
Ghazi T; Rink L; Sherr JL; Herold KC
Diabetes Care; 2014; 37(1):210-6. PubMed ID: 23939544
[TBL] [Abstract][Full Text] [Related]
8. Effects of acute NEFA manipulation on incretin-induced insulin secretion in participants with and without type 2 diabetes.
Astiarraga B; Chueire VB; Souza AL; Pereira-Moreira R; Monte Alegre S; Natali A; Tura A; Mari A; Ferrannini E; Muscelli E
Diabetologia; 2018 Aug; 61(8):1829-1837. PubMed ID: 29732475
[TBL] [Abstract][Full Text] [Related]
9. Impaired incretin-induced amplification of insulin secretion after glucose homeostatic dysregulation in healthy subjects.
Hansen KB; Vilsbøll T; Bagger JI; Holst JJ; Knop FK
J Clin Endocrinol Metab; 2012 Apr; 97(4):1363-70. PubMed ID: 22319034
[TBL] [Abstract][Full Text] [Related]
10. Beta and alpha cell function in metabolically healthy but obese subjects: relationship with entero-insular axis.
Calanna S; Piro S; Di Pino A; Maria Zagami R; Urbano F; Purrello F; Maria Rabuazzo A
Obesity (Silver Spring); 2013 Feb; 21(2):320-5. PubMed ID: 23404781
[TBL] [Abstract][Full Text] [Related]
11. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus.
Vilsbøll T; Krarup T; Sonne J; Madsbad S; Vølund A; Juul AG; Holst JJ
J Clin Endocrinol Metab; 2003 Jun; 88(6):2706-13. PubMed ID: 12788877
[TBL] [Abstract][Full Text] [Related]
12. Effect of meal composition on postprandial glucagon-like peptide-1, insulin, glucagon, C-peptide, and glucose responses in overweight/obese subjects.
Shah M; Franklin B; Adams-Huet B; Mitchell J; Bouza B; Dart L; Phillips M
Eur J Nutr; 2017 Apr; 56(3):1053-1062. PubMed ID: 26759261
[TBL] [Abstract][Full Text] [Related]
13. Increased postprandial GIP and glucagon responses, but unaltered GLP-1 response after intervention with steroid hormone, relative physical inactivity, and high-calorie diet in healthy subjects.
Hansen KB; Vilsbøll T; Bagger JI; Holst JJ; Knop FK
J Clin Endocrinol Metab; 2011 Feb; 96(2):447-53. PubMed ID: 21047927
[TBL] [Abstract][Full Text] [Related]
14. Impaired beta cell sensitivity to incretins in type 2 diabetes is insufficiently compensated by higher incretin response.
Tura A; Bagger JI; Ferrannini E; Holst JJ; Knop FK; Vilsbøll T; Mari A
Nutr Metab Cardiovasc Dis; 2017 Dec; 27(12):1123-1129. PubMed ID: 29162361
[TBL] [Abstract][Full Text] [Related]
15. Effects of meal size and composition on incretin, alpha-cell, and beta-cell responses.
Rijkelijkhuizen JM; McQuarrie K; Girman CJ; Stein PP; Mari A; Holst JJ; Nijpels G; Dekker JM
Metabolism; 2010 Apr; 59(4):502-11. PubMed ID: 19846181
[TBL] [Abstract][Full Text] [Related]
16. Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance.
Vollmer K; Holst JJ; Baller B; Ellrichmann M; Nauck MA; Schmidt WE; Meier JJ
Diabetes; 2008 Mar; 57(3):678-87. PubMed ID: 18057091
[TBL] [Abstract][Full Text] [Related]
17. High residual C-peptide likely contributes to glycemic control in type 1 diabetes.
Rickels MR; Evans-Molina C; Bahnson HT; Ylescupidez A; Nadeau KJ; Hao W; Clements MA; Sherr JL; Pratley RE; Hannon TS; Shah VN; Miller KM; Greenbaum CJ;
J Clin Invest; 2020 Apr; 130(4):1850-1862. PubMed ID: 31895699
[TBL] [Abstract][Full Text] [Related]
18. Meal sequence and glucose excursion, gastric emptying and incretin secretion in type 2 diabetes: a randomised, controlled crossover, exploratory trial.
Kuwata H; Iwasaki M; Shimizu S; Minami K; Maeda H; Seino S; Nakada K; Nosaka C; Murotani K; Kurose T; Seino Y; Yabe D
Diabetologia; 2016 Mar; 59(3):453-61. PubMed ID: 26704625
[TBL] [Abstract][Full Text] [Related]
19. Gut incretin hormones in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM)--evidence for decreased glucagon-like peptide 1 secretion during oral glucose ingestion in NIDDM twins.
Vaag AA; Holst JJ; Vølund A; Beck-Nielsen HB
Eur J Endocrinol; 1996 Oct; 135(4):425-32. PubMed ID: 8921824
[TBL] [Abstract][Full Text] [Related]
20. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients.
Creutzfeldt WO; Kleine N; Willms B; Orskov C; Holst JJ; Nauck MA
Diabetes Care; 1996 Jun; 19(6):580-6. PubMed ID: 8725855
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
